United Therapeutics UTHR has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $288.25, accompanied by a high estimate of $330.00 and a low estimate of $215.00. Marking an increase of 35.33%, the current average surpasses the previous average price target of $213.00.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of United Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Liana Moussatos | Wedbush | Maintains | Outperform | $308.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $215.00 | $213.00 |
| Roanna Ruiz | Leerink Partners | Announces | Outperform | $330.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on United Therapeutics analyst ratings.
About United Therapeutics
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Financial Insights: United Therapeutics
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 18.1%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 43.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.81%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): United Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 3.91%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
